سوق أدوية العلاج الكيميائي العالمي - اتجاهات الصناعة والتوقعات حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL CHEMOTHERAPY DRUG MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL CHEMOTHERAPY DRUG MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL CHEMOTHERAPY DRUG MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES MODEL

5 INDUSTRY INSIGHTS

5.1 PATENT ANALYSIS

5.1.1 PATENT LANDSCAPE

5.1.2 USPTO NUMBER

5.1.3 PATENT EXPIRY

5.1.4 EPIO NUMBER

5.1.5 PATENT STRENGTH AND QUALITY

5.1.6 PATENT CLAIMS

5.1.7 PATENT CITATIONS

5.1.8 PATENT LITIGATION AND LICENSING

5.1.9 FILE OF PATENT

5.1.10 PATENT RECEIVED CONTRIES

5.1.11 TECHNOLOGY BACKGROUND

5.2 DRUG TREATMENT RATE BY MATURED MARKETS

5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

5.4 PATIENT FLOW DIAGRAM

5.5 KEY PRICING STRATEGIES

5.6 KEY PATIENT ENROLLMENT STRATEGIES

5.7 INTERVIEWS WITH SPECIALIST

5.8 OTHER KOL SNAPSHOTS

6 EPIDEMIOLOGY

6.1 INCIDENCE OF ALL BY GENDER

6.2 TREATMENT RATE

6.3 MORTALITY RATE

6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

6.5 PATIENT TREATMENT SUCCESS RATES

7 MERGERS AND ACQUISITION

7.1 LICENSING

7.2 COMMERCIALIZATION AGREEMENTS

8 REGULATORY FRAMEWORK

8.1 REGULATORY APPROVAL PROCESS

8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

8.3 REGULATORY APPROVAL PATHWAYS

8.4 LICENSING AND REGISTRATION

8.5 POST-MARKETING SURVEILLANCE

8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIALS AND PHASE ANALYSIS

9.2 DRUG THERAPY PIPELINE

9.3 PHASE III CANDIDATES

9.4 PHASE II CANDIDATES

9.5 PHASE I CANDIDATES

9.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR CHEMOTHERAPY DRUG MARKET

Company Name Therapeutic Area

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE CHEMOTHERAPY DRUG MARKET

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved But Not Yest Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE CHEMOTHERAPY DRUG MARKET

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE CHEMOTHERAPY DRUG MARKET

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR CHEMOTHERAPY DRUG MARKET

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

10 MARKETED DRUG ANALYSIS

10.1 DRUG

10.1.1 BRAND NAME

10.1.2 GENERICS NAME

10.2 THERAPEUTIC INDIACTION

10.3 PHARACOLOGICAL CLASS OF THE DRUG

10.4 DRUG PRIMARY INDICATION

10.5 MARKET STATUS

10.6 MEDICATION TYPE

10.7 DRUG DOSAGES FORM

10.8 DOSAGES AVAILABILITY

10.9 PACKAGING TYPE

10.1 DRUG ROUTE OF ADMINISTRATION

10.11 DOSING FREQUENCY

10.12 DRUG INSIGHT

10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.

10.13.1 FORECAST MARKET OUTLOOK

10.13.2 CROSS COMPETITION

10.13.3 THERAPEUTIC PORTFOLIO

10.13.4 CURRENT DEVELOPMENT SCENARIO

11 MARKET ACCESS

11.1 10-YEAR MARKET FORECAST

11.2 CLINICAL TRIAL RECENT UPDATES

11.3 ANNUAL NEW FDA APPROVED DRUGS

11.4 DRUGS MANUFACTURER AND DEALS

11.5 MAJOR DRUG UPTAKE

11.6 CURRENT TREATMENT PRACTICES

11.7 IMPACT OF UPCOMING THERAPY

12 R & D ANALYSIS

12.1 COMPARATIVE ANALYSIS

12.2 DRUG DEVELOPMENTAL LANDSCAPE

12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

12.4 THERAPEUTIC ASSESSMENT

12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

13 MARKET OVERVIEW

13.1 DRIVERS

13.2 RESTRAINTS

13.3 OPPORTUNITIES

13.4 CHALLENGES

14 GLOBAL CHEMOTHERAPY DRUG MARKET, BY TYPE

14.1 OVERVIEW

14.2 MARKETED / APPROVED DRUGS

14.2.1 CYTOTOXIC DRUGS

14.2.1.1. BY TYPE

14.2.1.1.1. ALKYLATING AGENT

14.2.1.1.1.1 CISPLATIN

14.2.1.1.1.2 CHLORAMBUCIL

14.2.1.1.1.3 CYCLOPHOSPHAMIDE

14.2.1.1.1.4 MELPHALAN

14.2.1.1.1.5 CARBOPLATIN

14.2.1.1.1.6 OTHERS

14.2.1.1.2. ANTIMETABOLITES

14.2.1.1.2.1 AZACITIDINE

14.2.1.1.2.2 METHOTREXATE

14.2.1.1.2.3 FLUOROURACIL

14.2.1.1.2.4 FLUDARABINE

14.2.1.1.2.5 GEMCITABINE

14.2.1.1.2.6 CYTARABINE

14.2.1.1.2.7 OTHERS

14.2.1.1.3. TOPOISOMERASE INHIBITORS (I AND II)

14.2.1.1.3.1 IRINOTECAN

14.2.1.1.3.2 ETOPOSIDE

14.2.1.1.3.3 TOPOTECAN

14.2.1.1.3.4 OTHERS

14.2.1.1.4. ANTIMITOTIC DRUGS

14.2.1.1.4.1 CABAZITAXEL

14.2.1.1.4.2 VINCRISTINE

14.2.1.1.4.3 VINBLASTINE

14.2.1.1.4.4 OTHERS

14.2.1.1.5. OTHERS

14.2.1.2. BY DRUG TYPE

14.2.1.2.1. BRANDED

14.2.1.2.2. GENERICS

14.2.2 TARGETED DRUGS

14.2.2.1. BY TYPE

14.2.2.1.1. MONOCLONAL ANTIBODIES

14.2.2.1.1.1 TRASTUZUMAB

14.2.2.1.1.2 OFATUMUMAB

14.2.2.1.1.3 OBINUTUZUMAB

14.2.2.1.1.4 RITUXIMAB

14.2.2.1.1.5 ALEMTUZUMAB

14.2.2.1.1.6 BEVACIZUMAB

14.2.2.1.1.7 OTHERS

14.2.2.1.2. TYROSINE KINASE INHIBITORS

14.2.2.1.2.1 IMATINIB

14.2.2.1.2.2 DASATINIB

14.2.2.1.2.3 NILOTINIB

14.2.2.1.2.4 BOSUTINIB

14.2.2.1.2.5 SUNITINIB

14.2.2.1.2.6 PONATINIB

14.2.2.1.2.7 OTHERS

14.2.2.1.3. PROTEASOME INHIBITOR

14.2.2.1.3.1 CARFILZOMIB

14.2.2.1.3.2 BORTEZOMIB

14.2.2.1.3.3 OTHERS

14.2.2.1.4. OTHERS

14.2.2.2. BY DRUG TYPE

14.2.2.2.1. BRANDED

14.2.2.2.2. GENERICS

14.2.3 HORMONAL DRUGS

14.2.3.1. BY TYPE

14.2.3.1.1. OVARIAN FUNCTION BLOCKERS

14.2.3.1.1.1 GOSERELIN

14.2.3.1.1.2 LEUPRORELIN

14.2.3.1.1.3 TRIPTORELIN

14.2.3.1.2. ESTROGEN PRODUCTION BLOCKERS

14.2.3.1.2.1 AROMATASE INHIBITORS (AIS)

14.2.3.1.2.2 ANASTROZOLE

14.2.3.1.2.3 EXEMESTANE

14.2.3.1.2.4 LETROZOLE

14.2.3.1.3. ESTROGEN’S EFFECTS BLOCKERS

14.2.3.1.4. SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)

14.2.3.1.5. TAMOXIFEN (NOLVADEX)

14.2.3.1.6. TOREMIFENE (FARESTON)

14.2.3.1.7. FULVESTRANT (FASLODEX)

14.2.3.1.8. OTHER ANTIESTROGEN DRUGS

14.2.3.1.9. OTHERS

14.2.3.2. BY DRUG TYPE

14.2.3.2.1. BRANDED

14.2.3.2.2. GENERICS

14.2.4 ANTI-TUMOUR ANTIBIOTICS

14.2.4.1. ANTHRACYCLINES

14.2.4.1.1. EPIRUBICIN

14.2.4.1.2. MITOXANTRONE

14.2.4.1.3. VALRUBICIN

14.2.4.1.4. DAUNORUBICIN

14.2.4.1.5. DOXORUBICIN

14.2.4.1.6. IDARUBICIN

14.2.4.1.7. OTHERS

14.2.4.2. MISCELLANEOUS

14.2.4.2.1. BLEOMYCIN

14.2.4.2.2. DACTINOMYCIN

14.2.4.2.3. MITOMYCIN C

14.2.4.3. OTHERS

14.2.5 PLANT ALKALOIDS AND TERPENOIDS

14.2.5.1. CAMPTOTHECIN

14.2.5.2. ROHITUKINE

14.2.5.3. HARRINGTONINE

14.2.5.4. ACRONYCIN

14.2.5.5. THALICARPINE

14.2.5.6. ELLIPTICINE

14.2.5.7. USAMBARENSINE

14.2.5.8. MATRINES

14.2.5.9. OTHERS

14.2.6 TAXANES

14.2.6.1. PACLITAXEL

14.2.6.1.1. TAXOL

14.2.6.1.2. ANZATAX

14.2.6.1.3. PAXENE

14.2.6.1.4. ABRAXANE

14.2.6.2. DOCETAXEL

14.2.6.2.1. TAXOTERE

14.2.6.2.2. OTHERS

14.2.6.3. CABAZITAXEL

14.2.6.3.1. JEVTANA

14.2.6.3.2. OTHERS

14.2.7 PODOPHYLLOTOXIN

14.3 PIPELINE DRUGS

14.3.1 AMG 193

14.3.2 VERU 111

14.3.3 MBM-02

14.3.4 JZP351

14.3.5 MK-5890

14.3.6 UBLITUXIMAB

14.3.7 OFATUMUMAB (OMB 157)

14.3.8 BAT4706

14.3.9 BAT7104

14.3.10 ABP 798

14.3.11 OTHERS

15 GLOBAL CHEMOTHERAPY DRUG MARKET, BY DRUGS TYPE

15.1 OVERVIEW

15.2 BRANDED

15.2.1 PLATINOL AQ

15.2.2 LEUKERAN

15.2.3 CYTOXAN

15.2.4 ONUREG

15.2.5 ALKERAN IV

15.2.6 EVOMELA

15.2.7 ONXOL

15.2.8 PACLITAXEL NOVAPLUS

15.2.9 CYTOSAR-U

15.2.10 TARABINE PFS

15.2.11 OTHERS

15.3 GENERICS

16 GLOBAL CHEMOTHERAPY DRUG MARKET, BY ROUTE OF ADMINISTRATION

16.1 OVERVIEW

16.2 ORAL

16.2.1 TABLETS

16.2.2 CAPSULE

16.2.3 OTHERS

16.3 PARENTERAL

16.3.1 INTRAVENOUS

16.3.2 INTRAMUSCULAR

16.3.3 OTHERS

16.4 OTHERS

17 GLOBAL CHEMOTHERAPY DRUG MARKET, BY POPULATION TYPE

17.1 OVERVIEW

17.2 PEDIATRIC

17.3 ADULTS

17.4 GERIATRIC

18 GLOBAL CHEMOTHERAPY DRUG MARKET, BY GENDER

18.1 OVERVIEW

18.2 MALE

18.2.1 PEDIATRIC

18.2.2 ADULTS

18.2.3 GERIATRIC

18.3 FEMALE

18.3.1 PEDIATRIC

18.3.2 ADULTS

18.3.3 GERIATRIC

19 GLOBAL CHEMOTHERAPY DRUG MARKET, BY APPLICATION

19.1 OVERVIEW

19.2 ONCOLOGY/CANCER

19.2.1 LUNG CANCER

19.2.2 BREAST CANCER

19.2.3 COLORECTAL CANCER

19.2.4 PROSTATE CANCER

19.2.5 BLOOD CANCER

19.2.5.1. LEUKEMIA

19.2.5.2. NON-HODGKIN LYMPHOMA

19.2.5.3. HODGKIN LYMPHOMA

19.2.5.4. MULTIPLE MYELOMA

19.2.5.5. OTHERS

19.2.6 BLADDER CANCER

19.2.7 ENDOMETRIAL CANCER

19.2.8 KIDNEY CANCER

19.2.9 LIVER CANCER

19.2.10 PANCREATIC CANCER

19.2.11 THYROID CANCER

19.3 BONE MARROW DISEASES

19.4 IMMUNE SYSTEM DISORDERS

19.5 OTHERS

20 GLOBAL CHEMOTHERAPY DRUG MARKET, BY END USER

20.1 OVERVIEW

20.2 HOSPITALS

20.2.1 BY TYPE

20.2.1.1. PUBLIC

20.2.1.2. PRIVATE

20.2.2 BY LEVEL

20.2.2.1. TIER 1

20.2.2.2. TIER 2

20.2.2.3. TIER 3

20.3 SPECIALITY CLINICS

20.3.1 PUBLIC

20.3.2 PRIVATE

20.4 HOME HEALTHCARE

20.5 ONCOLOGY CENTRES

20.6 AMBUALTORY SURGICAL CENTERS

20.7 RESEARCH AND ACADEMIC INSTITUTES

20.7.1 GOVERNMENT

20.7.2 PRIVATE

20.8 OTHERS

21 GLOBAL CHEMOTHERAPY DRUG MARKET, BY DISTRIBUTION CHANNEL

21.1 OVERVIEW

21.2 DIRECT TENDER

21.3 RETAIL SALES

21.3.1 ONLINE

21.3.1.1. COMPANY WEBISTE

21.3.1.2. E-PHARMACY

21.3.1.3. OTHERS

21.3.2 OFFLINE

21.3.2.1. HOSPITAL PHARMACY

21.3.2.2. MEDICINE STORES

21.3.2.3. OTHERS

21.4 OTHERS

22 GLOBAL CHEMOTHERAPY DRUG MARKET, SWOT AND DBMR ANALYSIS

23 GLOBAL CHEMOTHERAPY DRUG MARKET, COMPANY LANDSCAPE

23.1 COMPANY SHARE ANALYSIS: GLOBAL

23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

23.3 COMPANY SHARE ANALYSIS: EUROPE

23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

23.5 MERGERS & ACQUISITIONS

23.6 NEW PRODUCT DEVELOPMENT & APPROVALS

23.7 EXPANSIONS

23.8 REGULATORY CHANGES

23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

24 GLOBAL CHEMOTHERAPY DRUG MARKET, BY REGION

GLOBAL CHEMOTHERAPY DRUG MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

24.1 NORTH AMERICA

24.1.1 U.S.

24.1.2 CANADA

24.1.3 MEXICO

24.2 EUROPE

24.2.1 GERMANY

24.2.2 U.K.

24.2.3 ITALY

24.2.4 FRANCE

24.2.5 SPAIN

24.2.6 RUSSIA

24.2.7 SWITZERLAND

24.2.8 TURKEY

24.2.9 BELGIUM

24.2.10 NETHERLANDS

24.2.11 DENMARK

24.2.12 SWEDEN

24.2.13 POLAND

24.2.14 NORWAY

24.2.15 FINLAND

24.2.16 REST OF EUROPE

24.3 ASIA-PACIFIC

24.3.1 JAPAN

24.3.2 CHINA

24.3.3 SOUTH KOREA

24.3.4 INDIA

24.3.5 SINGAPORE

24.3.6 THAILAND

24.3.7 INDONESIA

24.3.8 MALAYSIA

24.3.9 PHILIPPINES

24.3.10 AUSTRALIA

24.3.11 NEW ZEALAND

24.3.12 VIETNAM

24.3.13 TAIWAN

24.3.14 REST OF ASIA-PACIFIC

24.4 SOUTH AMERICA

24.4.1 BRAZIL

24.4.2 ARGENTINA

24.4.3 REST OF SOUTH AMERICA

24.5 MIDDLE EAST AND AFRICA

24.5.1 SOUTH AFRICA

24.5.2 EGYPT

24.5.3 BAHRAIN

24.5.4 UNITED ARAB EMIRATES

24.5.5 KUWAIT

24.5.6 OMAN

24.5.7 QATAR

24.5.8 SAUDI ARABIA

24.5.9 REST OF MEA

24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

25 GLOBAL CHEMOTHERAPY DRUG MARKET, COMPANY PROFILE

25.1 MARKETED MANUFACTURES

25.1.1 BRISTOL MYERS SQUIBB

25.1.1.1. COMPANY OVERVIEW

25.1.1.2. REVENUE ANALYSIS

25.1.1.3. GEOGRAPHIC PRESENCE

25.1.1.4. PRODUCT PORTFOLIO

25.1.1.5. RECENT DEVELOPMENTS

25.1.2 PFIZER INC.

25.1.2.1. COMPANY OVERVIEW

25.1.2.2. REVENUE ANALYSIS

25.1.2.3. GEOGRAPHIC PRESENCE

25.1.2.4. PRODUCT PORTFOLIO

25.1.2.5. RECENT DEVELOPMENTS

25.1.3 ASTRAZENECA

25.1.3.1. COMPANY OVERVIEW

25.1.3.2. REVENUE ANALYSIS

25.1.3.3. GEOGRAPHIC PRESENCE

25.1.3.4. PRODUCT PORTFOLIO

25.1.3.5. RECENT DEVELOPMENTS

25.1.4 BIOGEN + GENENTECH, INC. (F. HOFFMANN-LA ROCHE LTD)

25.1.4.1. COMPANY OVERVIEW

25.1.4.2. REVENUE ANALYSIS

25.1.4.3. GEOGRAPHIC PRESENCE

25.1.4.4. PRODUCT PORTFOLIO

25.1.4.5. RECENT DEVELOPMENTS

25.1.5 SANDOZ AG (NOVARTIES AG)

25.1.5.1. COMPANY OVERVIEW

25.1.5.2. REVENUE ANALYSIS

25.1.5.3. GEOGRAPHIC PRESENCE

25.1.5.4. PRODUCT PORTFOLIO

25.1.5.5. RECENT DEVELOPMENTS

25.1.6 CELLTRION HEALTHCARE CO., LTD.

25.1.6.1. COMPANY OVERVIEW

25.1.6.2. REVENUE ANALYSIS

25.1.6.3. GEOGRAPHIC PRESENCE

25.1.6.4. PRODUCT PORTFOLIO

25.1.6.5. RECENT DEVELOPMENTS

25.1.7 FRESENIUS HEALTH CARE GROUP

25.1.7.1. COMPANY OVERVIEW

25.1.7.2. REVENUE ANALYSIS

25.1.7.3. GEOGRAPHIC PRESENCE

25.1.7.4. PRODUCT PORTFOLIO

25.1.7.5. RECENT DEVELOPMENTS

25.1.8 BAXTER

25.1.8.1. COMPANY OVERVIEW

25.1.8.2. REVENUE ANALYSIS

25.1.8.3. GEOGRAPHIC PRESENCE

25.1.8.4. PRODUCT PORTFOLIO

25.1.8.5. RECENT DEVELOPMENTS

25.1.9 LUPIN

25.1.9.1. COMPANY OVERVIEW

25.1.9.2. REVENUE ANALYSIS

25.1.9.3. GEOGRAPHIC PRESENCE

25.1.9.4. PRODUCT PORTFOLIO

25.1.9.5. RECENT DEVELOPMENTS

25.1.10 ADVACARE PHARMA

25.1.10.1. COMPANY OVERVIEW

25.1.10.2. REVENUE ANALYSIS

25.1.10.3. GEOGRAPHIC PRESENCE

25.1.10.4. PRODUCT PORTFOLIO

25.1.10.5. RECENT DEVELOPMENTS

25.1.11 EXELIXIS, INC. + IPSEN PHARMA

25.1.11.1. COMPANY OVERVIEW

25.1.11.2. REVENUE ANALYSIS

25.1.11.3. GEOGRAPHIC PRESENCE

25.1.11.4. PRODUCT PORTFOLIO

25.1.11.5. RECENT DEVELOPMENTS

25.1.12 JOHNSON & JOHNSON SERVICES, INC.

25.1.12.1. COMPANY OVERVIEW

25.1.12.2. REVENUE ANALYSIS

25.1.12.3. GEOGRAPHIC PRESENCE

25.1.12.4. PRODUCT PORTFOLIO

25.1.12.5. RECENT DEVELOPMENTS

25.1.13 ASTELLAS PHARMA INC.

25.1.13.1. COMPANY OVERVIEW

25.1.13.2. REVENUE ANALYSIS

25.1.13.3. GEOGRAPHIC PRESENCE

25.1.13.4. PRODUCT PORTFOLIO

25.1.13.5. RECENT DEVELOPMENTS

25.1.14 AMNEAL PHARMACEUTICALS LLC.

25.1.14.1. COMPANY OVERVIEW

25.1.14.2. REVENUE ANALYSIS

25.1.14.3. GEOGRAPHIC PRESENCE

25.1.14.4. PRODUCT PORTFOLIO

25.1.14.5. RECENT DEVELOPMENTS

25.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

25.1.15.1. COMPANY OVERVIEW

25.1.15.2. REVENUE ANALYSIS

25.1.15.3. GEOGRAPHIC PRESENCE

25.1.15.4. PRODUCT PORTFOLIO

25.1.15.5. RECENT DEVELOPMENTS

25.1.16 CIPLA

25.1.16.1. COMPANY OVERVIEW

25.1.16.2. REVENUE ANALYSIS

25.1.16.3. GEOGRAPHIC PRESENCE

25.1.16.4. PRODUCT PORTFOLIO

25.1.16.5. RECENT DEVELOPMENTS

25.1.17 CHEPLAPHARM ARZNEIMITTEL GMBH

25.1.17.1. COMPANY OVERVIEW

25.1.17.2. REVENUE ANALYSIS

25.1.17.3. GEOGRAPHIC PRESENCE

25.1.17.4. PRODUCT PORTFOLIO

25.1.17.5. RECENT DEVELOPMENTS

25.1.18 ELI LILLY AND COMPANY

25.1.18.1. COMPANY OVERVIEW

25.1.18.2. REVENUE ANALYSIS

25.1.18.3. GEOGRAPHIC PRESENCE

25.1.18.4. PRODUCT PORTFOLIO

25.1.18.5. RECENT DEVELOPMENTS

25.1.19 JAZZ PHARMACEUTICALS, INC.

25.1.19.1. COMPANY OVERVIEW

25.1.19.2. REVENUE ANALYSIS

25.1.19.3. GEOGRAPHIC PRESENCE

25.1.19.4. PRODUCT PORTFOLIO

25.1.19.5. RECENT DEVELOPMENTS

25.1.20 THYMOORGAN PHARMAZIE GMBH (HIKMA PHARMACEUTICALS PLC)

25.1.20.1. COMPANY OVERVIEW

25.1.20.2. REVENUE ANALYSIS

25.1.20.3. GEOGRAPHIC PRESENCE

25.1.20.4. PRODUCT PORTFOLIO

25.1.20.5. RECENT DEVELOPMENTS

25.1.21 VITARIS INC.

25.1.21.1. COMPANY OVERVIEW

25.1.21.2. REVENUE ANALYSIS

25.1.21.3. GEOGRAPHIC PRESENCE

25.1.21.4. PRODUCT PORTFOLIO

25.1.21.5. RECENT DEVELOPMENTS

25.1.22 TEVA PHARMACEUTICAL INDUSTRIES LTD.

25.1.22.1. COMPANY OVERVIEW

25.1.22.2. REVENUE ANALYSIS

25.1.22.3. GEOGRAPHIC PRESENCE

25.1.22.4. PRODUCT PORTFOLIO

25.1.22.5. RECENT DEVELOPMENTS

25.1.23 SUN PHARMACEUTICAL INDUSTRIES LIMITED

25.1.23.1. COMPANY OVERVIEW

25.1.23.2. REVENUE ANALYSIS

25.1.23.3. GEOGRAPHIC PRESENCE

25.1.23.4. PRODUCT PORTFOLIO

25.1.23.5. RECENT DEVELOPMENTS

25.2 PIPELINE MANUFACTURES

25.2.1 AMGEN INC.

25.2.1.1. COMPANY OVERVIEW

25.2.1.2. REVENUE ANALYSIS

25.2.1.3. GEOGRAPHIC PRESENCE

25.2.1.4. PRODUCT PORTFOLIO

25.2.1.5. RECENT DEVELOPMENTS

25.2.2 GSK PLC

25.2.2.1. COMPANY OVERVIEW

25.2.2.2. REVENUE ANALYSIS

25.2.2.3. GEOGRAPHIC PRESENCE

25.2.2.4. PRODUCT PORTFOLIO

25.2.2.5. RECENT DEVELOPMENTS

25.2.3 BIO-THERA PHARMACEUTICALS CO., LTD.

25.2.3.1. COMPANY OVERVIEW

25.2.3.2. REVENUE ANALYSIS

25.2.3.3. GEOGRAPHIC PRESENCE

25.2.3.4. PRODUCT PORTFOLIO

25.2.3.5. RECENT DEVELOPMENTS

25.2.4 AMGEN AND ALLERGAN PLC. (ABBVIE)

25.2.4.1. COMPANY OVERVIEW

25.2.4.2. REVENUE ANALYSIS

25.2.4.3. GEOGRAPHIC PRESENCE

25.2.4.4. PRODUCT PORTFOLIO

25.2.4.5. RECENT DEVELOPMENTS

25.2.5 PROTHERAGEN INC.

25.2.5.1. COMPANY OVERVIEW

25.2.5.2. REVENUE ANALYSIS

25.2.5.3. GEOGRAPHIC PRESENCE

25.2.5.4. PRODUCT PORTFOLIO

25.2.5.5. RECENT DEVELOPMENTS

25.2.6 NOVARTIS AG

25.2.6.1. COMPANY OVERVIEW

25.2.6.2. REVENUE ANALYSIS

25.2.6.3. GEOGRAPHIC PRESENCE

25.2.6.4. PRODUCT PORTFOLIO

25.2.6.5. RECENT DEVELOPMENTS

25.2.7 MERCK & CO., INC.

25.2.7.1. COMPANY OVERVIEW

25.2.7.2. REVENUE ANALYSIS

25.2.7.3. GEOGRAPHIC PRESENCE

25.2.7.4. PRODUCT PORTFOLIO

25.2.7.5. RECENT DEVELOPMENTS

25.2.8 VERU INC.

25.2.8.1. COMPANY OVERVIEW

25.2.8.2. REVENUE ANALYSIS

25.2.8.3. GEOGRAPHIC PRESENCE

25.2.8.4. PRODUCT PORTFOLIO

25.2.8.5. RECENT DEVELOPMENTS

25.2.9 MATRIX BIOMED, INC.

25.2.9.1. COMPANY OVERVIEW

25.2.9.2. REVENUE ANALYSIS

25.2.9.3. GEOGRAPHIC PRESENCE

25.2.9.4. PRODUCT PORTFOLIO

25.2.9.5. RECENT DEVELOPMENTS

25.2.10 TG THERAPEUTICS, INC.

25.2.10.1. COMPANY OVERVIEW

25.2.10.2. REVENUE ANALYSIS

25.2.10.3. GEOGRAPHIC PRESENCE

25.2.10.4. PRODUCT PORTFOLIO

25.2.10.5. RECENT DEVELOPMENTS

26 RELATED REPORTS

27 CONCLUSION

28 QUESTIONNAIRE

29 ABOUT DATA BRIDGE MARKET RESEARCH